(+)-Erinacin A
CAS: 156101-08-5
Ref. 3D-GGA10108
| 1mg | Discontinued | ||
| 2mg | Discontinued | ||
| 5mg | Discontinued | ||
| 10mg | Discontinued | ||
| 25mg | Discontinued | ||
| 500µg | Discontinued |
Product Information
- Cyclohept[e]indene-8-carboxaldehyde, 2,3,3a,4,5,5a,6,7-octahydro-3a,5a-dimethyl-1-(1-methylethyl)-6-(β-D-xylopyranosyloxy)-, [3aR-(3aα,5aβ,6α)]-
- Erinacin A
- (3aR,5aR,6S)-2,3,3a,4,5,5a,6,7-Octahydro-3a,5a-dimethyl-1-(1-methylethyl)-6-(β-D-xylopyranosyloxy)cyclohept[e]indene-8-carboxaldehyde
- Cyclohept[e]indene-8-carboxaldehyde, 2,3,3a,4,5,5a,6,7-octahydro-3a,5a-dimethyl-1-(1-methylethyl)-6-(β-D-xylopyranosyloxy)-, (3aR,5aR,6S)-
(+)-Erinacin A is a potent natural product with promising anticancer properties. It is an analog of Erinacine A, which was isolated from the mushroom Hericium erinaceus. (+)-Erinacin A has been shown to inhibit the activity of kinases, including protein kinase C and Akt, which play important roles in cell survival and proliferation. This inhibition leads to apoptosis or programmed cell death in cancer cells. Studies have shown that (+)-Erinacin A exhibits selective cytotoxicity against various human cancer cell lines, including breast and lung cancer cells. Additionally, it has been found to be a potent inhibitor of Chinese hamster ovary (CHO) cell growth. Due to its potential as an anticancer agent, (+)-Erinacin A is being investigated for its medicinal properties as a kinase inhibitor and possible therapeutic agent for cancer treatment.
